FrancophonIA/ELRC3.0 huggingface dataset:
English: • patients with severe leucopenia, neutropenia, or thrombocytopenia (low levels of white cells or platelets in the blood);
Estonian: • patsiendid, kellel on raske leukopeenia, neutropeenia või trombotsütopeenia (vastavalt leukotsüütide ehk vere valgeliblede, neutrofiilide ehk teatud valgeliblede või trombotsüütide ehk vereliistakute vähesus);
English: • patients with severe liver or kidney disease;
Estonian: • raske maksa- või neeruhaigusega patsiendid;
English: Another study involving 1,886 patients who had had surgery showed that Xeloda together with oxaliplatin (another cancer medicine) was more effective than the combination of fluorouracil and folinic acid: patients taking Xeloda and oxaliplatin had 20% lower risk of getting cancer again or death compared with patients taking fluorouracil and folinic acid.
Estonian: Teises uuringus, milles osales 1886 opereeritud patsienti, selgus, et Xeloda koos oksaliplatiiniga (samuti vähiravim) oli efektiivsem kui fluorouratsiili ja foliinhappe kombinatsioon: Xelodat ja oksaliplatiini kasutanud patsientidel oli vähi taastekke või surma risk 20% väiksem kui fluorouratsiili ja foliinhapet kasutanud patsientidel.
English: How does Xeloda work?
Estonian: Kuidas Xeloda toimib?
English: Xeloda is used on its own or with other cancer medicines in patients who have had surgery for stage III or Dukes' stage C colon cancer;
Estonian: Xelodat kasutatakse ainuravimina või koos muude vähiravimitega patsientidel, keda on opereeritud käärsoolevähi III staadiumi (Dukesi skaala järgi C-staadiumi) tõttu;
English: Xeloda is a cancer medicine that is used to treat:
Estonian: Xeloda on vähiravim, mida kasutatakse järgmistel näidustustel:
English: What benefits of Xeloda have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Xeloda kasulikkus?
English: Xeloda is used with docetaxel (another cancer medicine) after treatment with anthracyclines (another type of cancer medicine) has failed.
Estonian: Xelodat kasutatakse koos dotsetakseeliga (samuti vähiravim) pärast seda, kui ravi antratsükliinidega (teist liiki vähiravimid) ei andnud tulemust.
English: An overview of Xeloda and why it is authorised in the EU
Estonian: Ülevaade ravimist Xeloda ja ELis müügiloa väljastamise põhjendus
English: The active substance in Xeloda, capecitabine, is a cytotoxic medicine (a medicine that kills cells that are dividing, such as cancer cells) that belongs to the group ‘anti-metabolites'.
Estonian: Xeloda toimeaine kapetsitabiin on antimetaboliitide rühma kuuluv tsütotoksiline ravim (ravim, mis hävitab jagunevaid rakke, näiteks vähirakke).
English: It can also be used on its own when treatment with both anthracyclines and taxanes (another type of cancer medicine) has failed or when further treatment with anthracyclines is not suitable for the patient.
Estonian: Xelodat tohib kasutada ka ainuravimina, kui ravi antratsükliinide ja taksaanidega (teist liiki vähiravimid) ei ole andnud tulemust või kui kordusravi antratsükliinidega patsiendile ei sobi.
English: Xeloda is used with other cancer medicines, including a platinum-containing cancer medicine such as cisplatin;
Estonian: Xelodat kasutatakse koos muude vähiravimitega, sh plaatinat sisaldava vähiravimiga (näiteks tsisplatiiniga);
English: Capecitabine is a ‘prodrug' that is converted to the medicine fluorouracil in the body, but more is converted in tumour cells than in normal tissues.
Estonian: Kapetsitabiin on eelravim, mis muundub organismis fluorouratsiiliks, kuid kasvajarakkudes tekib viimast rohkem kui tervetes kudedes.
English: Also, the results of a published study involving 1,002 patients showed that patients taking combinations of medicines that included Xeloda survived for a similar period as those taking combinations that included fluorouracil.
Estonian: 1002 patsiendiga avaldatud uuringu tulemused tõendasid, et nende patsientide elumus, kes kasutasid ravimite kombinatsioone, mis sisaldasid Xelodat, oli sarnane nende elumusega, kes kasutasid kombinatsioonravi fluorouratsiiliga.
English: It took 5.6 months for the disease to get worse in patients taking Xeloda and cisplatin, and 5.0 months in patients receiving fluorouracil and cisplatin.
Estonian: Xeloda ja tsisplatiini kombinatsiooni kasutanud patsientidel kulus haiguse süvenemiseni 5,6 kuud, fluorouratsiili ja tsisplatiini kombinatsiooni kasutanutel 5,0 kuud.
English: Xeloda has also been compared with the combination of fluorouracil and folinic acid, both used in combination with oxaliplatin, in 2 studies: the first involved 2,035 patients who had not been treated before, and the second involved 627 patients in whom previous treatment with irinotecan and a fluoropyrimidine (a group of cancer medicines that includes fluorouracil) had not worked.
Estonian: Esimeses uuringus osales 2035 varem ravimata patsienti ja teises 627 patsienti, kellel varasem ravi irinotekaani ja teatud fluoropürimidiiniga (fluorouratsiili sisaldav vähiravimite rühm) ei andnud tulemusi.
English: • colon (large bowel) cancer.
Estonian: • käärsoolevähk (jämesoolevähk).
English: In metastatic colorectal cancer, Xeloda taken on its own was as effective as the combination of fluorouracil and folinic acid in 2 studies involving 1,207 patients.
Estonian: Kahes uuringus, milles osales 1207 patsienti, oli Xeloda metastaatilise kolorektaalvähi ravis ainuravimina sama efektiivne kui fluorouratsiili ja foliinhappe kombinatsioon.
English: In advanced gastric cancer, Xeloda with cisplatin was as effective as a combination of fluorouracil and cisplatin in slowing down the disease in a study involving 316 patients.
Estonian: Uuringus, milles osales 316 patsienti, oli Xeloda koos tsisplatiiniga kaugelearenenud maovähi korral sama efektiivne haiguse kulu aeglustamisel kui fluorouratsiili ja tsisplatiini kombinatsioon.
English: In locally advanced or metastatic breast cancer, Xeloda with docetaxel was more effective than docetaxel on its own in a study involving 511 women.
Estonian: Uuringus, milles osales 511 naist, oli lokaalse kaugelearenenud või metastaatilise rinnavähi korral Xeloda ja dotsetakseeli kombinatsioon efektiivsem kui dotsetakseel ainuravimina.
English: Why is Xeloda authorised in the EU?
Estonian: ELis Xelodale väljastatud müügiloa põhjendus
English: They may request a re-examination of the opinion within 15 days of receipt of notification of this negative opinion.
Estonian: Ettevõtted võivad nõuda otsuse taasläbivaatamist 15 päeva jooksul alates negatiivse otsuse teate saamisest.
English: The cause of fibromyalgia is not known.
Estonian: Fibromüalgia põhjus ei ole teada.
English: These were measured using standard scales and questionnaires.
Estonian: Neid näitajaid mõõdeti standardsete skaalade ja küsimustikega.
English: It is used for the treatment of adults with the following diseases:
Estonian: Ravimit kasutatakse järgmiste haiguste ravimiseks täiskasvanutel:
English: International non-proprietary name (INN): duloxetine
Estonian: Rahvusvaheline mittekaubanduslik nimetus (INN): duloksetiin
English: • episodes of major depression;
Estonian: • raske depressiooni episoodid;
English: What is happening for duloxetine used for the treatment of other diseases?
Estonian: Mis toimub duloksetiini kasutamisel teiste haiguste raviks?
English: In all of the studies, the main measures of effectiveness were based on changes in the patients' symptoms, particularly pain levels, and their overall state of health.
Estonian: Kõigis uuringutes olid efektiivsuse peamiseks näitajaks muutused patsiendi sümptomites, eriti valu tugevuses ja nende üldises terviseseisundis.
English: Fibromyalgia can also cause other symptoms such as tenderness, stiffness, tiredness, anxiety and changes in how the patient sleeps, feels and thinks.
Estonian: Fibromüalgia võib põhjustada ka teisi sümptomeid, nagu näiteks tundlikkus, jäikus, väsimus, ärevus ja muutusi patsiendi unes, tundmustes ja mõtlemises.
English: Ref. EMEA/551181/2008
Estonian: London, 23. oktoober 2008 Viitedokument: EMEA/599096/2008
English: The change concerned an extension of indication to add the treatment of fibromyalgia.
Estonian: Muudatuse sisu oli näidustuste laiendamine fibromüalgia ravi näidustuse lisamiseks.
English: This prevents the active substance being destroyed by the acid in the stomach.
Estonian: See takistab toimeaine hävitamist maohappe toimel.
English: What documentation was presented to support this application?
Estonian: Mis dokumendid esitasid ettevõtted inimravimikomiteele oma taotluse toetuseks?
English: On 23 October 2008, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of a change to the marketing authorisation for the medicinal product Cymbalta/Xeristar 30 mg and 60 mg gastroresistant capsules.
Estonian: 23. oktoobril 2008 võttis inimravimikomitee vastu negatiivse otsuse, soovitades ravimi Cymbalta/Xeristar 30 mg ja 60 mg gastroresistentsete kapslite müügiloa muutmisest keelduda.
English: The fifth, a long-term study, compared the effects of two doses of Cymbalta/Xeristar over a year in 307 patients.
Estonian: Viiendas, pikaajalises uuringus võrreldi Cymbalta/Xeristari kahe annuse toimet ühe aasta jooksul 307 patsiendil.
English: Hence, the CHMP recommended that the change to the marketing authorisation be refused.
Estonian: Inimravimikomitee soovitas seepärast müügiloa muutmisest keelduda.
English: What were the major concerns that led the CHMP to recommend the refusal of the change to the marketing authorisation?
Estonian: Mis olid peamised probleemid, mille tõttu soovitas inimravimikomitee müügiloa muutmisest keelduda?
English: Cymbalta/Xeristar has been authorised since December 2004.
Estonian: Cymbaltale/Xeristarile anti müügiluba 2004. aasta detsembris.
English: It is available as gastroresistant capsules.
Estonian: Ravimit turustatakse gastroresistentsete kapslitena.
English: Since these neurotransmitters are thought to be involved in fibromyalgia, blocking their re-uptake into nerve cells is expected to improve the symptoms of the disease.
Estonian: Kuna arvatakse, et need neurotransmitterid osalevad fibromüalgia korral esinevates haigusprotsessides, võib nende närvirakkudesse tagasihaarde pärssimine leevendada haiguse sümptomeid.
English: There are no consequences on the use of Cymbalta/Xeristar, Ariclaim or Yentreve in their authorised indications, for which the balance of benefits and risks remains unchanged.
Estonian: Keeldumise otsusel ei ole tagajärgi Cymbalta/Xeristari, Ariclaimi või Yentreve kasutamist nende näidustuste raviks, mille kohta on müügiluba juba antud ning mille korral jääb kasulikkuse ja riski suhe muutumatuks.
English: By blocking their re-uptake, duloxetine increases the amount of these neurotransmitters in the spaces between these nerve cells, increasing the level of communication between the cells.
Estonian: Nende tagasihaarde pärssimisega suurendab duloksetiin nende neurotransmitterite arvu närvirakkude vahel, suurendades seega närvirakkude signaalivahetust.
English: The CHMP also concluded that the long-term study was insufficient to show the effectiveness of the medicine and that a long-term study comparing Cymbalta/Xeristar with placebo would be needed.
Estonian: Lisaks otsustas inimravimikomitee, et pikaajaline uuring ei olnud ravimi tõhususe tõendamiseks piisav ja et tuleb läbi viia pikaajaline uuring, milles võrreldakse Cymbaltat/Xeristari ja platseebot.
English: The results of five studies involving a total of 1,718 adults with fibromyalgia were presented to the CHMP to support the application.
Estonian: Taotluse toetamiseks esitati inimravimikomiteele viie uuringu tulemused, milles osales kokku 1718 fibromüalgiaga täiskasvanud patsienti.
English: In the short-term studies, the CHMP considered that the effect of Cymbalta/Xeristar was too small to be relevant for patients: there was no clear demonstration of improvement in symptoms, and the modest effects of Cymbalta/Xeristar could be due to the medicine's effect of improving the patients' mood.
Estonian: Inimravimikomitee arvas, et lühiajalistes uuringutes oli Cymbalta/Xeristari toime patsientidele olulisena olemiseks liiga väike: selge tõestus sümptomite paranemisele puudus ning Cymbalta/Xeristari tagasihoidlike toimete põhjuseks võis olla selle patsientide meeleolu parandav toime.
English: Four of the studies were short-term, lasting between three and six months, and comparing Cymbalta/Xeristar with placebo (a dummy treatment) in a total of 1,411
Estonian: Neli uuringut olid lühiajalised kestusega kolm kuni kuus kuud ning neis võrreldi Cymbaltat/Xeristari platseeboga (näiv ravim) kokku 1411 patsiendil.
English: Cymbalta/Xeristar is a medicine containing the active substance duloxetine.
Estonian: Cymbalta/Xeristar on ravim, mille toimeaine on duloksetiini.
English: The companies informed the CHMP that there are currently no ongoing clinical trials with Cymbalta/Xeristar in fibromyalgia patients in Europe.
Estonian: Ettevõtted teatasid inimravimikomiteele, et praegu ei ole Euroopas pooleli ühtegi Cymbalta/Xeristari kliinilist uuringut fibromüalgiaga patsientidel.
English: What is Cymbalta/Xeristar?
Estonian: Mis on Cymbalta/Xeristar?
English: Questions and answers on recommendation for the refusal of a change to the marketing authorisation for Cymbalta/Xeristar
Estonian: Teave soovituse kohta keelduda muutmast müügiluba ravimile Cymbalta/Xeristar
English: The companies that applied for authorisation are Eli Lilly Nederland B.V. (for Cymbalta) and Boehringer Ingelheim International GmbH (for Xeristar).
Estonian: (Cymbalta jaoks) ja Boehringer Ingelheim International GmbH (Xeristari jaoks).
English: The CHMP was concerned that the effectiveness of Cymbalta/Xeristar in treating fibromyalgia had not been shown sufficiently.
Estonian: Inimravimikomitee arvas, et Cymbalta/Xeristari tõhusust fibromüalgia ravis ei ole piisavalt tõendatud.
English: Cymbalta/Xeristar was expected to be used in fibromyalgia patients with or without depression.
Estonian: Cymbaltat/Xeristari kavatseti kasutada fibromüalgia raviks patsientidel, kellel on depressioon või kellel seda ei ole.
English: At that point in time, the CHMP was of the opinion that the benefits of Cymbalta/Xeristar in the treatment of fibromyalgia did not outweigh its risks.
Estonian: Sel ajal arvas inimravimikomitee, et Cymbalta/Xeristari kasulikkus fibromüalgia ravis ei ületa ravimiga kaasnevaid riske.
English: Duloxetine, under the names Ariclaim and Yentreve, is also authorised for use in stress urinary incontinence.
Estonian: Duloksetiin on Ariclaimi ja Yentreve nimede all heaks kiidetud pingutus-kusepidamatuse raviks.
English: What are the consequences of the refusal for patients in clinical trials with Cymbalta/Xeristar?
Estonian: Kuidas mõjutab keeldumine praegu Cymbalta/Xeristari kliinilistes uuringutes osalevaid patsiente?
English: It works by preventing the neurotransmitters 5-hydroxytryptamine (also called serotonin) and noradrenaline from being taken back up into nerve cells in the brain and spinal cord.
Estonian: Cymbalta/Xeristari toimeaine duloksetiin on serotoniini ja noradrenaliini tagasihaarde inhibiitor, mis pärsib neurotransmitterite 5-hüdroksütrüptamiini (serotoniin) ja noradrenaliini tagasihaaret peaaju ja seljaaju närvirakkudesse.
English: How is Cymbalta/Xeristar expected to work?
Estonian: Milline on Cymbalta/Xeristari eeldatav toime?
English: What was Cymbalta/Xeristar expected to be used for?
Estonian: Milleks kavatseti Cymbaltat/Xeristari kasutada?
English: Cymbalta/Xeristar was also expected to be used to treat adults with fibromyalgia, a disease causing long-lasting, widespread pain and painful responses to touch.
Estonian: Fibromüalgia on haigus, mis põhjustab pikaajalist ulatuslikku valu ja valureaktsiooni puudutusele.
English: EU/1/01/179/001 Osigraft
Estonian: EU/1/01/179/001
English: 3.3 mg Powder for suspension for implantation
Estonian: 3,3 mg Pulber suspensiooni valmistamiseks ja siirdamiseks
English: Intraosseous use Vial (glass)
Estonian: Intraossaalne Viaal (klaas)
English: 1 vial l t o r
Estonian: 1 viaal l n a
English: Content
Estonian: Osigraft
English: Invented name Strength Pharmaceutical Form Route of Administration
Estonian: Müügiloa nr Euroopa Liidus Ravimi väljamõeldud nimetus Tugevus Ravimvorm ManustamisteePakendi iseloomustus Pakendi sisu
English: Pregabalin Mylan Pharma is available as capsules (25, 50, 75, 100, 150, 200, 225 and 300 mg) and can only be obtained with a prescription.
Estonian: Pregabalin Mylan Pharmat turustatakse kapslitena (25, 50, 75, 100, 150, 200, 225 ja 300 mg) ja see on retseptiravim.
English: The full EPAR for Pregabalin Mylan Pharma can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ravimi Pregabalin Mylan Pharma kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: To stop treatment with Pregabalin Mylan Pharma the dose should be reduced gradually, over at least a week.
Estonian: Ka ravi katkestamine ravimiga Pregabalin Mylan Pharma peab toimuma järk-järgult, vähemalt ühe nädala jooksul.
English: What measures are being taken to ensure the safe and effective use of Pregabalin Mylan Pharma?
Estonian: Mis meetmed võetakse, et tagada Pregabalin Mylan Pharma ohutu ja efektiivne kasutamine?
English: Pregabalin Mylan Pharma pregabalin
Estonian: Pregabalin Mylan Pharma pregabaliin
English: As for every medicine, the company provided studies on the quality of Pregabalin Mylan Pharma.
Estonian: Nagu iga ravimi korral, esitas ettevõte uuringud ravimi Pregabalin Mylan Pharma kvaliteedi kohta.
English: This means that Pregabalin Mylan Pharma contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Lyrica.
Estonian: See tähendab, et Pregabalin Mylan Pharma sisaldab sama toimeainet ja toimib samal viisil kui võrdlusravim Lyrica, millel juba on Euroopa Liidus müügiluba.
English: Studies on the benefits and risks of the active substance in the approved uses have already been carried out with the reference medicine, Lyrica, and do not need to be repeated for Pregabalin Mylan Pharma.
Estonian: Võrdlusravimiga Lyrica on juba tehtud toimeaine heakskiidetud kasutamisviiside kasulikkuse ja riski uuringud ning neid ei ole vaja ravimiga Pregabalin Mylan Pharma korrata.
English: The active substance in Pregabalin Mylan Pharma, pregabalin, is similar in structure to the body's own ‘neurotransmitter' gamma‑amino butyric acid (GABA), but has very different biological effects.
Estonian: Pregabalin Mylan Pharma toimeaine pregabaliin sarnaneb struktuurilt organismi looduslikule neurotransmitterile gamma-aminobutüürhappele (GABA), kuid on teistsuguse bioloogilise toimega.
English: Because Pregabalin Mylan Pharma is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Pregabalin Mylan Pharma on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pregabalin Mylan Pharma has been shown to have comparable quality and to be bioequivalent to Lyrica.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Pregabalin Mylan Pharma võrreldav kvaliteet ja bioekvivalentsus ravimiga Lyrica.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Pregabalin Mylan Pharma on 25 June 2015.
Estonian: Euroopa Komisjon andis Pregabalin Mylan Pharma müügiloa, mis kehtib kogu Euroopa Liidus, 25. juunil
English: Pregabalin Mylan Pharma is a medicine used to treat adults with the following conditions:
Estonian: Pregabalin Mylan Pharma on ravim, mida kasutatakse järgmiste haigusseisundite raviks täiskasvanutel:
English: After one week, the dose can be increased to 300 mg per day.
Estonian: Ühe nädala möödudes võib ööpäevast annust suurendada 300 mg-ni. Annust tohib suurendada, kuni on saavutatud efektiivseim annus.
English: What is Pregabalin Mylan Pharma and what is it used for?
Estonian: Mis on Pregabalin Mylan Pharma ja milleks seda kasutatakse?
English: The Committee recommended that Pregabalin Mylan Pharma be approved for use in the EU.
Estonian: Komitee soovitas Pregabalin Mylan Pharma kasutamise Euroopa Liidus heaks kiita.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pregabalin Mylan Pharma have been included in the summary of product characteristics and the package leaflet.
Estonian: Ravimi Pregabalin Mylan Pharma ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: For practical information about using Pregabalin Mylan Pharma, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Pregabalin Mylan Pharma kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: This is a summary of the European public assessment report (EPAR) for Pregabalin Mylan Pharma.
Estonian: See on ravimi Pregabalin Mylan Pharma Euroopa avaliku hindamisaruande kokkuvõte.
English: For more information about treatment with Pregabalin Mylan Pharma, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Pregabalin Mylan Pharmaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: It is not intended to provide practical advice on how to use Pregabalin Mylan Pharma.
Estonian: Hindamisaruandes ei anta Pregabalin Mylan Pharma kasutamise praktilisi nõuandeid.
English: Pregabalin Mylan Pharma is a ‘generic medicine'.
Estonian: Pregabalin Mylan Pharma on geneeriline ravim.
English: Other information about Pregabalin Mylan Pharma
Estonian: Muu teave Pregabalin Mylan Pharma kohta
English: Why is Pregabalin Mylan Pharma approved?
Estonian: Miks Pregabalin Mylan Pharma heaks kiideti?
English: Therefore, the CHMP's view was that, as for Lyrica, the benefit outweighs the identified risk.
Estonian: Seetõttu on inimravimite komitee arvamusel, et nagu ka Lyrica korral, ületab ravimi Pregabalin Mylan Pharma kasulikkus sellega kaasnevad riskid.
English: Pregabalin Mylan Pharma contains the active substance pregabalin.
Estonian: Pregabalin Mylan Pharma sisaldab toimeainena pregabaliini.
English: How does Pregabalin Mylan Pharma work?
Estonian: Kuidas Pregabalin Mylan Pharma toimib?
English: How is Pregabalin Mylan Pharma used?
Estonian: Kuidas Pregabalin Mylan Pharmat kasutatakse?
English: How has Pregabalin Mylan Pharma been studied?
Estonian: Kuidas Pregabalin Mylan Pharmat uuriti?
English: What are the benefits and risks of Pregabalin Mylan Pharma?
Estonian: Milles seisneb Pregabalin Mylan Pharma kasulikkus ja mis riskid ravimiga kaasnevad?
English: Don't delay.
Estonian: Ärge viivitage.
English: This will reduce the risk of any problems.
Estonian: See vähendab võimalike probleemide riski.
English: This will help to make the treatment more effective.
Estonian: See aitab muuta ravi tõhusamaks.
English: The possibility of sensitisation should be taken into account.
Estonian: Arvestada tuleb sensibiliseerumise võimalusega.
English: Let it dry completely before you use it again.
Estonian: Laske täielikult kuivada, enne kui kasutate seda uuesti.
English: S=susceptible, R=resistant
Estonian: S=tundlik, R=resistentne
English: See ‘Conditions you need to look out for' in Section 4.
Estonian: Vt „Seisundid, millele tuleb tähelepanu pöörata“ lõigus 4.
English: Don't drive or use machines if you do not feel well.
Estonian: Ärge juhtige autot ega töötage masinatega, kui te ei tunne ennast hästi.
English: 5 insufficient evidence that the species in question is a good target for therapy with the drug.
Estonian: 5 ebapiisavad tõendid selle kohta, et vastav liik on ravi hea sihtmärk.